The oral JAK1 and JAK2 inhibitor baricitinib (OLUMIANT) has been approved by the Therapeutic Goods Administration for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately, or who are intolerant, to one or more disease-modifying anti-rheumatic drugs. RA-BEAM study The RA-BEAM study published in the New England Journal of ...
Baricitinib (OLUMIANT) approved in Australia for treatment of moderate to severe RA
21 Mar 2018
Sponsored by Eli Lilly Australia Pty Ltd